AI-enabled brain imaging company icometrix receives CPT III code

icometrix, a brain imaging AI company based in Belgium, has announced that it has been granted a CPT III code by the American Medical Association. This code enables reimbursement for its FDA-cleared brain MRI quantification software.

The AI-supported software developed by icometrix provides quantitative analysis of cerebral MRI scans, offering metrics that assist clinicians in diagnosing, monitoring, and evaluating treatment responses in patients with various neurological conditions, including Alzheimer's disease, dementia, multiple sclerosis, epilepsy, stroke, and Parkinson's disease.

The issuance of the CPT code allows qualified healthcare professionals to report their utilisation of icometrix's brain imaging AI software as a practice expense.

In 2019, icometrix secured $18 million in funding to expand its brain software. The company obtained FDA clearance for its icobrain-ctp offering in February 2020. Additionally, icometrix recently received a grant from the Michael J. Fox Foundation to collaborate with a professor at Stanford Medicine in researching brain MRI biomarkers for Parkinson's disease. Moreover, it received a grant from the National Institute for Health and Care Research to accelerate research in multiple sclerosis imaging.

Neurophet, a South Korean health tech firm, is also utilising AI software to aid healthcare providers in diagnosing brain disorders. In April, Neurophet obtained certification from Singapore's Health Sciences Authority for its AI-enabled software, which assists in diagnosing degenerative brain diseases.

Click here to read the original news story.